Skip to main content
Premium Trial:

Request an Annual Quote

Epigenetics Feinberg: loss of imprinting increases risk of cancer

Premium

Andrew Feinberg, a professor of molecular medicine at Johns Hopkins University, has been having a real chicken-or-the-egg problem in his studies with cancer epigenetics. “One of the puzzling things [in the field] has been how to know what occurs first — whether an epigenetic change arises before the tumor arises or after,” he says.

To get to the bottom of the mystery, Feinberg and his team decided to study epigenetic changes that are present in normal cells and see how it compares to a disorder involving such a change. They homed in on a particular epigenetic change — loss of imprinting — and designed experiments to see how it affected the insulin-like growth factor II, or IGF2, gene often connected with colorectal cancer. “We made a mouse model to test the hypothesis that loss of imprinting really does increase tumor risk,” Feinberg says. The team combined a mouse with loss of imprinting of the gene “with a mouse that’s prone to developing intestinal tumors,” he says. “Basically the mice had both loss of imprinting and a mutation in the APC gene.” As it turns out, mice that had the loss of imprinting had double the likelihood of developing tumors as the other mice.

That study has raised plenty of other questions for Feinberg, who has been studying epigenetic changes for years. “One of the questions that we’re really interested in is which genes are really mediating this,” he says. “We’re … interested in understanding the IGF2 signaling pathway and which particular downstream effects are responsible for this phenotype.”

Feinberg isn’t the only one intrigued by these results. “From the epidemiological community there’s actually a lot of interest” in this kind of work, he says.

— Meredith Salisbury

http://biolchem.bs.jhmi.edu/bcmb/Faculty_person.asp?PersonID=585

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.